sage of Platelet Rich Plasma in Treatment of Chronic Non-Healing Diabetic Ulcers
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
- Registration Number
- CTRI/2021/11/038085
- Lead Sponsor
- Dr PSIMS and RF
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
chronic non healing ulcers more than 10 cm square
ulcer more than 4 week duration
sugar levels maintained under control
hypertensive patients
age above 18 years
hemoglobin more than 9g/dl
Exclusion Criteria
systemic disorders like CVS diseases, liver failure, renal failure
connective tissue disorders
pregnant women
ulcer site containing necrotic tissue
platelets less than 1,00,000/microlitre
any infection
acute ischemia, gangrene
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To analyse the efficacy of platelet rich plasma in treating chronic non healing diabetic ulcers <br/ ><br>To assess the time of treatment for complete wound closureTimepoint: The total duration of treatment is expected to take approximately 6 weeks
- Secondary Outcome Measures
Name Time Method To analyse the efficacy of platelet rich plasma in treating chronic non healing diabetic ulcersTimepoint: In these 3months of study
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie PRP's efficacy in chronic diabetic ulcers with T2DM complications?
How does Platelet Rich Plasma compare to standard-of-care treatments for non-healing T2DM ulcers in clinical trials?
Which biomarkers are associated with successful healing of T2DM ulcers using Platelet Rich Plasma therapy?
What adverse events are reported in Platelet Rich Plasma treatment for T2DM-related chronic ulcers and how are they managed?
Are there combination therapies involving Platelet Rich Plasma and other compounds for T2DM ulcer treatment in clinical research?